Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 2,220 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ADD Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Whole Grain and Fiber Addition Study

NCT03623308
View directory record Official record
Conditions
Healthy
Interventions
Fiber cereal
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

NCT00968812
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Canagliflozin (JNJ-28431754), Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
43
States / cities
Calera, Alabama • Gilbert, Arizona • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Not applicable Interventional Results available

ADHD Treatment for Latino Families

NCT02317692
View directory record Official record
Conditions
ADHD
Interventions
Parent training
Behavioral
Lead sponsor
Marquette University
Other
Eligibility
5 Years to 13 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 2 Interventional

Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma

NCT00183911
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastric Cancer
Interventions
floxuridine, 5-Fluorouracil, leucovorin, External Beam Radiotherapy, Surgery
Drug · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 2 Interventional

Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.

NCT01012375
View directory record Official record
Conditions
Adult ADHD
Interventions
AZD1446, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Los Alamitos, California • Fort Myers, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 25, 2026, 9:39 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Methodology of Super-Early Training of Developer Engineers and Leading Analysts With a Diagnosis of ADHD/ASD for Ensuring the Engineering Sovereignty of the State: Time Horizon: 2026-2038-2050

NCT07845292
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Voice of Sleep "MamaBee" training modules (Fairy Tales)
Device
Lead sponsor
Pisareva Citadel Group LLC
Other
Eligibility
8 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
NewYork, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 9:39 PM EDT
Completed No phase listed Observational

Central Nervous System Disease in HIV-infected Children on HAART

NCT00110331
View directory record Official record
Conditions
HIV Infections, Central Nervous System Diseases
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 2Phase 3 Interventional

Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1

NCT00061087
View directory record Official record
Conditions
ADHD, Opioid-Related Disorders, Cocaine Dependence
Interventions
Methylphenidate, Bupropion, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 4 Interventional

Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD

NCT00318981
View directory record Official record
Conditions
Adult ADHD
Interventions
Concerta
Drug
Lead sponsor
University of Maryland, College Park
Other
Eligibility
Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 25, 2026, 9:39 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

NCT03781414
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
CFZ533, Tacrolimus - MMF - corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 4 Interventional Results available

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

NCT00607919
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Dyslexia
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 16 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
16
States / cities
Irvine, California • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Not applicable Interventional Results available

Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder

NCT00118911
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Cognitive behavioral therapy (CBT), Relaxation techniques and education about ADHD
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Not applicable Interventional

Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder

NCT00381407
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Organizational Skills Training, Contingency management (CM)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
8 Years to 11 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 4 Interventional Results available

Bupropion for ADHD in Adolescents With Substance Use Disorder

NCT00936299
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence, Cannabis Use Disorder
Interventions
Bupropion, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 19 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT00318448
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Zolpidem (SL800750)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 25, 2026, 9:39 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00592007
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
Fulvestrant and Erlotinib
Drug
Lead sponsor
Lyudmila Bazhenova, M.D.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 25, 2026, 9:39 PM EDT
Not listed No phase listed Observational

Does Atrial Fibrillation (AF) Termination Without Additional Ablation Influence Outcome?

NCT01696344
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
PVAI, PVAI + ablation of extraPV triggers
Procedure
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 1 Interventional

Methylphenidate Treatment for Cocaine Abuse and ADHD - 1

NCT00136734
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders
Interventions
Methylphenidate, placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 25, 2026, 9:39 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity

NCT01017263
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Glucose Intolerance, Obesity
Interventions
Lis-dexamphetamine
Drug
Lead sponsor
Duke University
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Oct 25, 2026, 9:39 PM EDT
Not listed Phase 1Phase 2 Interventional

Intervening Early With Neglected Children

NCT02093052
View directory record Official record
Conditions
Conduct Disorder, ADHD, Depression
Interventions
Attachment and Biobehavioral Catch-up, Developmental Education for Families
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
6 Years to 8 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

NCT01532648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX®, Placebo, 5-ASA
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Anaheim, California • Lakewood, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 25, 2026, 9:39 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

NCT03247088
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Filgrastim, Fludarabine, Mycophenolate Mofetil, Sorafenib, Tacrolimus
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Not applicable Interventional

Central Executive Training for ADHD

NCT03042338
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
CET: Central Executive Training, CET: Comparison Executive Training
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
8 Years to 13 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 25, 2026, 9:39 PM EDT